Details

Autor(en) / Beteiligte

• Niemeijer, Anna-Larissa N
• Oprea-Lager, Daniela E
• Huisman, Marc C
• Hoekstra, Otto S
• Boellaard, Ronald
• de Wit-van der Veen, Berlinda J
• Bahce, Idris
• Vugts, Daniëlle J
• van Dongen, Guus A M S
• Thunnissen, Erik
• Smit, Egbert F
• de Langen, Adrianus J

Titel

Study of 89 Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer

Ist Teil von

• Journal of Nuclear Medicine, 2022-03, Vol.63 (3), p.362-367

Ort / Verlag

United States

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However, not all patients respond to therapy. Better understanding of in vivo drug behavior may help in the selection of patients who will benefit the most. NSCLC patients eligible for pembrolizumab monotherapy as first- or later-line therapy were enrolled. Patients received 2 injections of Zr-pembrolizumab, 1 without a preceding dose of pembrolizumab and 1 with a preceding dose of 200 mg of pembrolizumab, directly before tracer injection. Up to 4 PET/CT scans were obtained after tracer injection. After imaging acquisition, patients were treated with 200 mg of pembrolizumab every 3 wk. Tumor uptake and tracer biodistribution were visually assessed and quantified as the SUV. Tumor tracer uptake was correlated with PD-1 and PD-L1 expression and response to pembrolizumab treatment. Twelve NSCLC patients were included. One patient experienced grade 3 myalgia after tracer injection. Zr-pembrolizumab was observed in the blood pool, liver, and spleen. Tracer uptake was visualized in 47.2% of 72 tumor lesions measuring ΒΧΡ20 mm in the long-axis diameter, and substantial uptake heterogeneity was observed within and between patients. Uptake was higher in patients with a response to pembrolizumab treatment ( = 3) than in patients without a response ( = 9), although this finding was not statistically significant (median SUV , 11.4 vs. 5.7; = 0.066). No significant correlations were found with PD-L1 or PD-1 immunohistochemistry. Zr-pembrolizumab injection was safe, with only 1 grade 3 adverse event-possibly immune-related-in 12 patients. Zr-pembrolizumab tumor uptake was higher in patients with a response to pembrolizumab treatment but did not correlate with PD-L1 or PD-1 immunohistochemistry.